Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
Publication/Presentation Date
6-1-2024
Abstract
PURPOSE: There is significant interest in identifying complete responders to neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) to potentially avoid removal of a pathologically benign bladder. However, clinical restaging after NAC is highly inaccurate. The objective of this study was to develop a next-generation sequencing-based molecular assay using urine to enhance clinical staging of patients with bladder cancer.
METHODS: Urine samples from 20 and 44 patients with bladder cancer undergoing RC were prospectively collected for retrospective analysis for molecular correlate analysis from two clinical trials, respectively. The first cohort was used to benchmark the assay, and the second was used to determine the performance characteristics of the test as it correlates to responder status as measured by pathologic examination.
RESULTS: First, to benchmark the assay, known mutations identified in the tissue (M
CONCLUSION: M
Volume
8
First Page
2300362
Last Page
2300362
ISSN
2473-4284
Published In/Presented At
Satyal, U., Valentine, H., Liu, D., Slifker, M., Lallas, C. D., Trabulsi, E. J., Bukavina, L., Szeto, L., Hoffman-Censits, J. H., Mouw, K. W., Faltas, B. M., Grivas, P., Ibragimova, I., Porten, S. P., Van Allen, E. M., Geynisman, D. M., Parker, D. C., O'Neill, J. P., Drevik, J., Christianson, S. S., … Abbosh, P. H. (2024). Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO precision oncology, 8, e2300362. https://doi.org/10.1200/PO.23.00362
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
38865671
Department(s)
Administration and Leadership
Document Type
Article